Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Most policies still exclude weight-loss medications under general exclusions unless they are part of the treatment of a ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...

Most recently, some users of a miracle drug helping people to lose weight have reported it made their penis appear larger.

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...